Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Suparna Wedam(Center for Cancer Research), Sandra M. Swain(Roche (Switzerland))

Journal of Clinical Oncology

January 4, 2006

10.1200/jco.2005.03.4645

Cited by 523

Related Papers

Targeting HER2-positive breast cancer: advances and future directions

|Nature Reviews Drug Discovery|2022|1k

Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive, First-Line Metastatic Breast Cancer

|Journal of Clinical Oncology|2014|370

Phase I Trial of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Docetaxel in Patients with Metastatic Breast Cancer

|Clinical Cancer Research|2004|68